PMID- 32780229
OWN - NLM
STAT- MEDLINE
DCOM- 20210112
LR  - 20230917
IS  - 1432-1041 (Electronic)
IS  - 0031-6970 (Print)
IS  - 0031-6970 (Linking)
VI  - 77
IP  - 1
DP  - 2021 Jan
TI  - Safety of hydroxychloroquine in COVID-19 and other diseases: a systematic review 
      and meta-analysis of 53 randomized trials.
PG  - 13-24
LID - 10.1007/s00228-020-02962-5 [doi]
AB  - INTRODUCTION: Many concerns still exist regarding the safety of 
      hydroxychloroquine (HCQ) in the treatment of Coronavirus Disease 2019 (COVID-19). 
      OBJECTIVES: The purpose of this study was to evaluate the safety of HCQ in the 
      treatment of COVID-19 and other diseases by performing a systematic review and 
      meta-analysis. METHODS: Randomized controlled trials (RCTs) reporting the safety 
      of HCQ in PubMed, Embase, and Cochrane Library were retrieved starting from the 
      establishment of the database till June 5, 2020. Literature screening, data 
      extraction, and assessment of risk bias were performed independently by two 
      reviewers. RESULTS: We identified 53 eligible studies involving 5496 patients. 
      The meta-analysis indicated that the risk of adverse effects (AEs) in the HCQ 
      group was significantly increased compared with that in the control group (RD 
      0.05, 95%CI, 0.02 to 0.07, P = 0.0002), and the difference was also statistically 
      significant in the COVID-19 subgroup (RD 0.15, 95%CI, 0.07 to 0.23, P = 0.0002) 
      as well as in the subgroup for other diseases (RD 0.03, 95%CI, 0.01 to 0.04, 
      P = 0.003). CONCLUSIONS: HCQ is associated with a high total risk of AEs compared 
      with the placebo or no intervention in the overall population. Given the small 
      number of COVID-19 participants included, we should be cautious regarding the 
      conclusion stating that HCQ is linked with an increase incidence of AEs in 
      patients with COVID-19, which we hope to confirm in the future through 
      well-designed and larger sample size studies.
FAU - Chen, Can
AU  - Chen C
AD  - Department of Pharmacy, Zhongshan Hospital, Fudan University, Shanghai, 200032, 
      China.
FAU - Pan, Kunming
AU  - Pan K
AD  - Department of Pharmacy, Zhongshan Hospital, Fudan University, Shanghai, 200032, 
      China.
FAU - Wu, Bingjie
AU  - Wu B
AD  - Department of Rheumatology, Zhongshan Hospital, Fudan University, Shanghai, 
      200032, China.
FAU - Li, Xiaoye
AU  - Li X
AD  - Department of Pharmacy, Zhongshan Hospital, Fudan University, Shanghai, 200032, 
      China.
FAU - Chen, Zhangzhang
AU  - Chen Z
AD  - Department of Pharmacy, Zhongshan Hospital, Fudan University, Shanghai, 200032, 
      China.
FAU - Xu, Qing
AU  - Xu Q
AD  - Department of Pharmacy, Zhongshan Hospital, Fudan University, Shanghai, 200032, 
      China.
FAU - Li, Xiaoyu
AU  - Li X
AD  - Department of Pharmacy, Zhongshan Hospital, Fudan University, Shanghai, 200032, 
      China. li.xiaoyu@zs-hospital.sh.cn.
FAU - Lv, Qianzhou
AU  - Lv Q
AUID- ORCID: 0000-0002-0866-1546
AD  - Department of Pharmacy, Zhongshan Hospital, Fudan University, Shanghai, 200032, 
      China. lv.qianzhou@zs-hospital.sh.cn.
LA  - eng
GR  - No.shslczdzk06504/Key Clinical Specialty of Shanghai (Clinical Pharmacy)/
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20200811
PL  - Germany
TA  - Eur J Clin Pharmacol
JT  - European journal of clinical pharmacology
JID - 1256165
RN  - 4QWG6N8QKH (Hydroxychloroquine)
SB  - IM
MH  - Cardiotoxicity/etiology
MH  - Gastrointestinal Tract/drug effects
MH  - Humans
MH  - Hydroxychloroquine/*adverse effects
MH  - Outcome Assessment, Health Care
MH  - Publication Bias
MH  - *SARS-CoV-2
MH  - Skin/drug effects
MH  - *COVID-19 Drug Treatment
PMC - PMC7417776
OTO - NOTNLM
OT  - COVID-19
OT  - Hydroxychloroquine
OT  - Randomized controlled trial
OT  - Safety
OT  - Systematic review
COIS- The authors declare that they have no conflict of interest.
EDAT- 2020/08/12 06:00
MHDA- 2021/01/13 06:00
PMCR- 2020/08/11
CRDT- 2020/08/12 06:00
PHST- 2020/04/28 00:00 [received]
PHST- 2020/07/15 00:00 [accepted]
PHST- 2020/08/12 06:00 [pubmed]
PHST- 2021/01/13 06:00 [medline]
PHST- 2020/08/12 06:00 [entrez]
PHST- 2020/08/11 00:00 [pmc-release]
AID - 10.1007/s00228-020-02962-5 [pii]
AID - 2962 [pii]
AID - 10.1007/s00228-020-02962-5 [doi]
PST - ppublish
SO  - Eur J Clin Pharmacol. 2021 Jan;77(1):13-24. doi: 10.1007/s00228-020-02962-5. Epub 
      2020 Aug 11.